Although the GLP1 agonists, such as liraglutide, semaglutide and tirzepatide, have demonstrated clinical effectiveness in addressing obesity, it is important to note that these drugs have also been associated with certain side effects during dose escalation, including constipation, diarrhoea, nausea, dyspepsia and sarcopenia [13, 16]. The gene discussed is GLP1R; the disease is Obesity.